May 27, 2022 / 12:00PM GMT
Tyler Ehler -
Good morning, everyone, and thank you for dialing in today. Yesterday, after market hours, we published a press release sharing our updated Phase II clinical data with a data cutoff date of March 29, 2022.
In today's discussion, we'll go through uliledlimab's key differentiating factors, the most updated Phase II clinical data as well as our global clinical development plan.
With that, I'll hand it over to Dr. Zhu.
Andrew X. Zhu - I-Mab - Member of Scientific Advisory Board, President & Director
Thank you, Tyler. Thank you all for joining this call, particularly with ASCO just approaching us next week.
During today's meeting, we would like to share with you the latest encouraging Phase II clinical data of our differentiated CD73 antibody uliledlimab.
In early 2022, we submitted an abstract of uliledlimab the initial Phase II data to ASCO, with the data cutoff date of December 13, 2021. Since then, we're very pleased that the data has matured significantly. Therefore, after the ASCO embargo, we would like to take
I-Mab TJD5 Phase 2 Clinical Trial Data Update Call Transcript
May 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers